Between Week 0 and 24, 78% of patients in the ustekinumab group and 67% of patients in the placebo group had at least one adverse event. Approximately half the patients in each group experienced the most common type of adverse event, which was infection. No deaths, treatment-emergent opportunistic infections, herpes zoster, tuberculosis or malignancies were reported during the study period.
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomized, controlled study. Lancet. 2018 Oct 13;392(10155):1330–1339.